Makindo Medical Notes"One small step for man, one large step for Makindo" |
|
---|---|
Download all this content in the Apps now Android App and Apple iPhone/Pad App | |
MEDICAL DISCLAIMER: The contents are under continuing development and improvements and despite all efforts may contain errors of omission or fact. This is not to be used for the assessment, diagnosis, or management of patients. It should not be regarded as medical advice by healthcare workers or laypeople. It is for educational purposes only. Please adhere to your local protocols. Use the BNF for drug information. If you are unwell please seek urgent healthcare advice. If you do not accept this then please do not use the website. Makindo Ltd. |
Related Subjects: |Hodgkin Lymphoma |Non Hodgkin Lymphoma |Diffuse large B-cell lymphoma |Intravascular large B-cell lymphoma |Mantle cell lymphoma |Marginal Zone Lymphoma |Gastric (MALT) Lymphoma |Primary CNS Lymphoma (PCNSL) |Burkitt's lymphoma |Follicular Lymphoma
Most of the patients remain incurable and, in 10 years, 15% to 28% of cases will transform into an aggressive phenotype, typically diffuse large B-cell lymphoma (DLBCL) which usually requires more intensive types of treatment.
The introduction of anti-CD20 monoclonal antibody (Rituximab) has definitely improved the outcome of these patients as shown by many studies